LENZ (LENZ)
Commercializes VIZZ, an FDA-approved aceclidine eye drop for adult presbyopia.
Something off on this page? Send us feedback.
Sells VIZZ, a prescription eye drop for adult presbyopia, through U.S. pharmacy and e-pharmacy channels. International activity is handled through licensing and distribution partners, while the business reports one operating segment and depends on post-approval commercial execution, third-party manufacturing, and partner-led ex-U.S. development.
Commercializes VIZZ, the company's single marketed product, for adult presbyopia. The eye drop moved the issuer from late-stage clinical development to U.S. launch after FDA approval.
Sells in the United States through wholesalers serving retail pharmacies and through a direct-to-patient e-pharmacy partner. Outside the United States, market access runs through partners covering Greater China, South Korea and Southeast Asia, Canada, and parts of the Middle East.
Operates as one segment from Solana Beach, CA, with commercial infrastructure now more important than clinical trial execution. Pivotal trial work is substantially completed, and the context reports no ongoing clinical trials.
Business dependencies sit in product adoption, self-pay demand, third-party manufacturing, and partner execution outside the United States.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | Citigroup | Downgrade | ||
| Aug 12, 2026 | Piper Sandler | Reiterate | Rating: —Target: $12 | Target: $7 |
| May 12, 2026 | Piper Sandler | Downgrade | Target: $67 | Target: $12 |
| Oct 27, 2025 | H.C. Wainwright | Target | Target: — | Target: $56 |
| Oct 10, 2025 | Piper Sandler | Reiterate | Rating: —Target: $51 | Target: $67 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $220.0M · Total debt $122.0K · Total assets $236.6M · Shareholders' equity $219.3M
- Revenue
- $5.5M
- Operating income
- −$34.2M
- Net income
- −$31.9M
HistoryDividendAnnual yield
| Institutions | 111.05% | 34.89M shares | |
|---|---|---|---|
| 152 holders · as of Jun 30, 2026 | |||
| Insiders | 6.35% | 1.99M shares | |
| 6 holders · as of Mar 30, 2026 | |||
| Strategic holders | 5.78% | 1.81M shares | |
| 1 holder · as of Oct 2, 2025 | |||
| Adds to | 123.18% | ||
31.42M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 123.18%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 13.30% | 4.18M | as of Jun 30, 2026 |
Alpha Wave Global, LPInstitution | 11.50% | 3.61M | as of Jun 30, 2026 |
FMR LLCInstitution | 11.33% | 3.56M | as of Jun 30, 2026 |
Versant Venture Management, LLCInstitution | 8.46% | 2.66M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.30% | 2.29M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 27, 2026 | Daniel R. Chevallard | officer: Chief Financial Officer | +7,500 | $8.57 |
| Mar 27, 2026 | Evert B. Schimmelpennink | director, officer: President, CEO and Secretary | +28,089 | $8.95 |
| Mar 27, 2026 | Jeffrey P. George | director | +5,592 | $8.92 |
| Nov 17, 2025 | Shawn Olsson | officer: Chief Commercial Officer | −10,000 | $26.10 |
| Nov 7, 2025 | James W. Mccollum | director | +10,500 | $22.79 |
- AbbVie
Branded Vuity incumbent in pharmacologic presbyopia drops
- Amneal Pharmaceuticals
Lower-cost generic pilocarpine substitute for Vuity
- Alcon
Global eye-care substitute across contacts and IOLs
- Viatris
Commercial-rights holder for phentolamine presbyopia sNDA
- Johnson & Johnson
Large-scale ACUVUE substitute for presbyopia correction
- Bausch + Lomb
Public eye-care substitute through multifocal lenses
- CooperCompanies
CooperVision multifocal lens alternative for presbyopia
- Opus Genetics
Development owner behind phentolamine presbyopia program
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LENZ | $4.13 | +0.12% | $127.9M | — | — | 6.0 | +9.7% |
| AbbVie | $265.01 | −0.10% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Amneal Pharmaceuticals | $19.62 | +0.62% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Alcon | $65.72 | +0.20% | $31.64B | 49.9 | 17.3 | 2.9 | +7.5% |
| Viatris | $17.15 | −0.17% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Johnson & Johnson | $268.15 | −0.42% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Bausch + Lomb | $17.31 | −0.11% | $6.00B | — | 17.4 | 1.1 | +9.1% |
| CooperCompanies | $54.70 | −1.08% | $10.56B | 18.5 | 12.1 | 2.5 | +0.6% |
| Opus Genetics | $5.15 | 0.00% | $431.0M | — | — | 43.7 | −73.8% |
| Median | 41.4 | 17.4 | 2.7 | +7.0% |